Quality Evaluation of Chinese Diabetes Management Guidelines based on AGREE II and AGREE-China-Reference-Cited by-同舟云学术

Quality Evaluation of Chinese Diabetes Management Guidelines based on AGREE II and AGREE-China

Published:2023-04-18 Issue:2 Volume:2 Page:109-113
ISSN:2958-4396
Container-title:Academic Journal of Management and Social Sciences
language:
Short-container-title:AJMSS

Author:

Hu Hanyi,Cai Dongxia,Zhao Yanjiao,Chen Yongfa

Abstract

The purpose of this study is to verify the applicability of the Chinese clinical practice guideline evaluation tool (AGREE-China) by evaluating the diabetes mellitus (DM) guidelines, and to compare its characteristics with the clinical guideline research and evaluation tool II (AGREE II), in order to provide reference for clinical practice and subsequent revision of guidelines.

Publisher

Darcy & Roy Press Co. Ltd.

Reference33 articles.

1. Li Y, Teng D, Shi X, et al. “Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study,” BMJ, Vol. 369, pp. 997, 2020.

2. Cao Lizhen. “Analysis of common irrational medication problems in digestive internal medicine clinical patients with diabetes mellitus,” Diabetes New World, Vol. 20(18), pp. 195-196, 2017.

3. Zhang Yue, Zhang Shijing, Zhou Zhichao, et al. “Development and inspiration of international clinical guideline evaluation tools,” Chinese Journal of Medical Library and Information Science, Vol. 24(01), pp. 11-16, 2015.

4. Wang Liying, Liu Mengyu, Wang Yuexi, et al. “Review on the evaluation status of clinical diagnosis and treatment guidelines in China,” Chinese Journal of Traditional Chinese Medicine, Vol. 31(4), pp. 1316-1319, 2016.

5. Wang Ji-yao, Wang Qiang, Wang Xiao-qin, et al. “Development and preliminary validation of the appraisal of China's clinical practice guidelines evaluation system,” Chinese Medical Journal, Vol. 98(20), pp. 1544-1548, 2018.